ClinicalTrials.Veeva

Menu
C

Chatham County Health Department | Clinical Trials Unit

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Emtricitabine
Tenofovir Alafenamide
TAF
Islatravir
Bictegravir
Lenacapavir
FTC
Rilpivirine
Doravirine
ISL

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 22 total trials

Dose Ranging, Switch Study of Islatravir (ISL) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013]

This is a randomized, controlled, double-blind, study to evaluate the safety and tolerability of islatravir (ISL) + ulonivirine based on review of th...

Active, not recruiting
HIV-1 Infection
Drug: Islatravir
Drug: Placebo to Ulonivirine

The primary objective of this study is to evaluate the efficacy of oral weekly islatravir (ISL) in combination with lenacapavir (LEN) in virologicall...

Active, not recruiting
HIV-1 Infection
Drug: B/F/TAF
Drug: LEN

The goal of this clinical study is to learn more about the experimental drugs GS-1720 and GS-4182; to compare the combination of GS-1720 and GS-4182...

Enrolling
HIV-1-Infection
Drug: Placebo to Match BVY
Drug: Placebo to Match GS1720/GS-4182 FDC

The goal of this clinical study is to learn more about the safety and efficacy of switching to a once weekly tablet of islatravir/lenacapavir (ISL/LE...

Enrolling
HIV-1-Infection
Drug: Antiretroviral Combinations
Drug: ISL/LEN

The primary objective of this study is to evaluate the antiviral activity of lenacapavir (formerly GS-6207) administered as an add-on to a failing re...

Active, not recruiting
HIV-1-infection
Drug: Optimized Background Regimen (OBR)
Drug: Oral Lenacapavir Placebo

This study will evaluate the safety and efficacy of a switch to MK-8591A (a fixed dose combination of doravirine and islatravir) in human immunodefic...

Active, not recruiting
HIV Infection
Drug: Placebo to BIC/FTC/TAF
Drug: Placebo to FDC DOR/ISL

Trial sponsors

Gilead Sciences logo
Merck Sharp & Dohme (MSD) logo
Janssen (J&J Innovative Medicine) logo
ViiV Healthcare logo
T

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems